Ofirnoflast

N/A

Report date: 2026/02/26 20:00:22
NME

Base Information

Drug NameOfirnoflast
Drug Alias NameHT-6184
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine/threonine-protein kinase Nek7 inhibitorsNACHT, LRR and PYD domains-containing protein 3 inhibitors
TargetsSerine/threonine-protein kinase Nek7NACHT, LRR and PYD domains-containing protein 3
Therapy Area/IndicationsPainInflammationObesity +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Arab EmiratesIndia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesHalia Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesHalia Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsPainMyelodysplastic SyndromesAnemia
Inactive IndicationsInflammationObesityDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A